SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
|Articles|June 7, 2018
- June 2018 (Vol. 39, No. 06)
- Volume 39
- Issue 6
The acne supplement
Acne may primarily be a genetic condition, but one that is compounded by environmental and social influences, shows a twins study published in the Journal of Drugs in Dermatology (JDD). This study is among a select group of studies featured in this month's acne supplement.
Advertisement
Articles in this issue
over 8 years ago
Melanoma diagnosis by physician or PA not always straightforwardover 8 years ago
Pulsed dye laser fails surgical scarsover 8 years ago
Calming inflammation in common skin conditionsover 8 years ago
Cimzia receives positive CHMP opinion for plaque psoriasisover 8 years ago
FDA approves Tafinlar with Mekinist for melanomaover 8 years ago
SPSSCS names Donna Erb new presidentover 8 years ago
My employee has a needlestick injury. Now what?Advertisement
Related to this article
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Severity, Response Timing, and Lab Monitoring in Alopecia Areata Care
5